International Journal of Science and Research Archive
eISSN: 2582-8185
Cross Ref DOI: 10.30574/ijsra
Journal homepage: https://ijsra.net/

(Review Article)

Check for updates

Analytical method development and validation of antiviral drugs for HIV

Shrutika Sanjay Awachat *, Snehal Vijay Kalbande, Srushti Rajiv Raut, Trupti Raju Changade, Snehashish Sharadrao Sarnaik, Kishore Rodge and R. H. Kale

PRMSS Anuradha College of Pharmacy, Chikhli, India.

International Journal of Science and Research Archive, 2025, 15(01), 1618-1646

Publication history: Received on 18 March 2025; revised on 26 April 2025; accepted on 28 April 2025

Article DOI: https://doi.org/10.30574/ijsra.2025.15.1.1253

Abstract

This comprehensive overview takes into account a crucial function within the development and testing of analytical techniques that guarantee the effects, safety, and exceptional of antiviral tablets used for HIV treatment. In this evaluation, standards, technical, normative frameworks, and problems are systematically taken into consideration, and the drug is quantitatively determined and characterized. The main pastimes are to be very effective inside the mass evaluation of the mass evaluation and different advanced techniques of the liquid chromatography (VEGH), the liquid chromatography (LC-MS/MS), the discussion of worldwide hints, the consideration of stability, and innovation remark. Thanks to the mixing of cutting-edge literature and problem studies, this evaluation gives a roadmap for researchers and regulators who focus on the complexity of drug analysis on HIV.

Keywords: Analytical Method Development; Antiretroviral Drugs; HIV Treatment; HPLC Validation; LC-MS/MS; ICH Guidelines; Drug Stability

1. Introduction

Human Immunodeficiency Virus (HIV): The Human Immunodeficiency Virus (HIV) is a worldwide public health hazard, affecting lots and heaps of people globally. HIV attacks the immune gadget, specifically that specialize in CD4+ T cells, which might be essential for the frame's defence against infections. without remedy, HIV progresses to acquired immunodeficiency syndrome (AIDS), a scenario where the immune gadget becomes seriously weakened, most important to lifestyles-threatening opportunistic infections and cancers.[3]

considering its discovery inside the early 1980s, HIV has claimed hundreds and thousands of lives; but advances in antiretroviral remedy ARTt) have converted it from a lethal disorder into a doable continual circumstance. artwork entails an aggregate of drug treatments that suppresses viral replication, allowing human beings with HIV to live lengthy, wholesome lives.[3]

however clinical development, stressful situations stay, which includes drug resistance, adherence issues, and get right of entry to to remedy in low-resource settings. moreover, the development of correct analytical techniques for quantifying antiviral tablets in prescribed drugs and organic samples is vital for making sure drug efficacy, safety, and regulatory compliance. .[3]

This assessment explores the analytical techniques, validation methods, and regulatory suggestions vital for HIV drug analysis, highlighting the significance of sturdy methodologies in advancing HIV treatment and research. .[3]

* Corresponding author: Shrutika Sanjay Awachat

2. Types of HIV

There are two main types of the Human Immunodeficiency Virus (HIV):

2.1. HIV-1

2.1.1. Definition

HIV-1 is the most common and pathogenic strain of the Human Immunodeficiency Virus, responsible for the global HIV/AIDS pandemic.[3]

2.1.2. Key Features

- Origin: Transmitted from chimpanzees to humans (SIVcpz)
- Global Prevalence: Causes ~95% of HIV infections worldwide
- Subtypes: Multiple groups (M, N, O, P) with Group M having 9 subtypes (A-K)
- Virulence: More aggressive than HIV-2, progresses faster to AIDS without treatment

2.1.3. Transmission

- Sexual contact (vaginal/anal)
- Blood exposure (needles, transfusions)
- Mother-to-child (pregnancy, delivery, breastfeeding)

2.1.4. Treatment

- Managed with antiretroviral therapy (ART)
- Requires combination of ≥3 drugs from different classes
- Without treatment, leads to AIDS in ~8-10 years

2.1.5. Global Impact

- Sub-Saharan Africa most affected (especially subtype C)
- Subtype B dominant in Americas/Europe
- Ongoing vaccine research due to high mutation rate

2.1.6. Challenges

- Rapid mutation leads to drug resistance
- Stigma limits testing/treatment access
- Requires lifelong daily medication

2.2. HIV-2

2.2.1. Definition

HIV-2 is a less common type of the Human Immunodeficiency Virus, primarily found in West Africa. [3]

2.2.2. Key Features

- Origin: Transmitted from sooty mangabeys (SIVsm)
- Prevalence: Accounts for <5% of global HIV cases
- Virulence: Less aggressive than HIV-1, slower disease progression
- Subtypes: 8 groups (A-H), with A and B being most common

2.2.3. Transmission

- Same routes as HIV-1 but less efficient
- Lower sexual and vertical (mother-to-child) transmission rates

2.2.4. Diagnosis & Treatment

- Requires specific tests (may be missed by standard HIV-1 tests)

- Naturally resistant to some antiretrovirals (e.g., NNRTIs like nevirapine)
- Protease inhibitors and integrase inhibitors remain effective

2.2.5. Geographic Distribution

- Endemic in West Africa (Guinea-Bissau, Senegal, Ivory Coast)
- Rare cases in Europe/India linked to West African connections

2.2.6. Clinical Significance

- Longer asymptomatic period (may not need treatment for years)
- Lower viral loads compared to HIV-1
- Less risk of progression to AIDS

Table 1 Key Differences Between HIV-1 and HIV-2

Feature	**HIV-1**	**HIV-2**
Prevalence	Global (~95% of infections)	Mostly West Africa (~5%)
Virulence	More aggressive, faster progression	Slower progression to AIDS
Transmission	Higher risk (sexual, blood, vertical)	Lower transmission efficiency
Drug Resistance	Develops resistance over time	Naturally resistant to some ARVs
Diagnosis	Detected by standard HIV tests	May require specific HIV-2 tests

3. Causes of HIV Infection: Detailed Explanation

HIV (Human Immunodeficiency Virus) is caused by transmission of the virus through specific bodily fluids. The primary causes/modes of transmission include:

3.1. Sexual Transmission (Most Common)

3.1.1. Unprotected vaginal/anal sex: Highest risk through:

- Receptive anal sex (18x higher risk than insertive)
- Vaginal intercourse (female-to-male transmission less efficient)
- Presence of STIs (syphilis, herpes) increases susceptibility 3-5x

3.1.2. Oral sex: Extremely low risk unless open sores present

- Risk factors:
  - High viral load (increases transmission risk 10-20x)
  - Traumatic sex causing mucosal tears
  - Multiple partners/sex work

3.2. Blood Exposure

3.2.1. Needle sharing:

- 0.67% per exposure risk (IV drug use)
- Contaminated medical equipment (rare in developed countries)

3.2.2. Transfusions/Transplants:

- Now extremely rare (<1 in 2 million in screened blood)
- Historical outbreaks (e.g. hemophiliacs in 1980s)

3.2.3. Occupational exposure:

- Needlestick injuries (0.3% transmission risk)

- Mucous membrane exposure (0.09% risk)

3.3. Mother-to-Child (Vertical) Transmission

- During pregnancy: 15-30% risk without intervention
- Delivery: 10-20% additional risk (exposure to blood/vaginal fluids)
- Breastfeeding: 5-20% transmission risk
- Prevention:
    - ART reduces risk to <1%
    - C-section delivery when viral load >1000 copies/mL
    - Formula feeding in resource-rich settings

3.4. Other Rare Modes

- Tattoos/piercings: With unsterilized equipment
- Pre-chewed food: Documented in HIV+ caregivers
- Deep kissing: Only theoretical risk with bleeding gums

3.4.1. Key Biological Factors

- Viral subtypes: HIV-1 Group M (most transmissible)
- Host genetics: CCR5-Δ32 mutation provides resistance
- Acute infection phase: 26x more infectious due to high viral load

3.4.2. Non-Transmission Routes (Myth Busting)

- ✗ Casual contact
- ✗ Mosquito bites
- ✗ Saliva/tears/sweat
- ✗ Toilet seats

3.4.3. Prevention Strategies

- Barrier methods (condoms reduce risk by 80-95%)
- PrEP (99% effective when taken correctly)
- PEP (72-hour post-exposure window)
- Universal precautions in healthcare



Figure 1 Understanding and preventing HIV Transmission Pathways

4. Structural enhancements [1]

4.1. Glossary of Abbreviations and Technical Terms

Below is a curated glossary of essential abbreviations and technical terms relevant to HIV/AIDS research and clinical practice. Definitions are drawn from authoritative sources and reflect current usage [1]

Table 2 Glossary of Abbreviations and Technical Terms

Abbreviation/Term	Definition
AIDS	Acquired Immunodeficiency Syndrome; the most advanced stage of HIV infection.
ART	Antiretroviral Therapy; the use of medications to treat HIV infection.
ARV	Antiretroviral (drug); a medication used to prevent the replication of HIV.
CD4 count	A laboratory test measuring the number of CD4+ T lymphocytes per mm^3 of blood; used to assess immune function in people with HIV.
HAART	Highly Active Antiretroviral Therapy; a combination of three or more antiretroviral drugs to suppress HIV replication and progression.
HIV	Human Immunodeficiency Virus; the virus that causes AIDS by attacking the immune system.
PLHIV	People Living with HIV; refers to individuals diagnosed with HIV infection.
Pharmacogenomics	The study of how genes affect a person's response to drugs, enabling personalized therapy.
LC-MS/MS	Liquid Chromatography–Tandem Mass Spectrometry; an advanced analytical technique used for precise drug quantification in biological samples.
bNAbs	Broadly Neutralizing HIV-1 Antibodies; antibodies that can neutralize a wide range of HIV strains
INIs	Integrase Inhibitors; a class of ARVs that block the HIV enzyme integrase, preventing viral DNA from integrating into the host genome.
MTCT	Mother-to-Child Transmission; the passage of HIV from a mother to her child during pregnancy, childbirth, or breastfeeding.

4.2. Introduction to Analytical Method Development and Validation [1]

Analytical method development and validation are critical steps in the pharmaceutical industry, especially during the development of antiviral drugs for HIV. Analytical methods are used to detect, identify, quantify, and characterize drugs and their impurities. The accuracy and reliability of these methods ensure that the final product meets quality standards for purity, potency, safety, and efficacy. [1]

- Method development involves selecting appropriate techniques to analyze a drug substance or product, optimizing the experimental conditions, and ensuring the method is suitable for its intended purpose. [1]
- Method validation confirms that the developed method consistently produces reliable and reproducible results. It is performed in accordance with ICH guidelines, which include parameters such as specificity, accuracy, precision, linearity, limit of detection (LOD), limit of quantification (LOQ), and robustness. [1]

For antiviral drugs used in the treatment of HIV, accurate analytical methods are essential to monitor drug quality, pharmacokinetics, and stability, and to ensure compliance with regulatory requirements. [1]



Figure 2 Analytical Method for HIV Antivirals

4.3. Analytical Methods for Antiviral Drugs (HIV)

- High-Performance Liquid Chromatography (HPLC)
- Liquid Chromatography–Mass Spectrometry (LC-MS/MS)
- Thin Layer Chromatography (TLC)
- Dissolution Testing
- Stability-Indicating Assays

4.4. High-Performance Liquid Chromatography (HPLC) in HIV Drug Analysis: [14]

4.4.1. Introduction to HPLC

High-Performance Liquid Chromatography (HPLC) is one of the most widely used analytical techniques in pharmaceutical research and quality control, especially for antiviral drugs used in HIV therapy. It allows for precise and accurate quantification, identification, and purity assessment of both active pharmaceutical ingredients (APIs) and formulated products. [14]

HPLC is essential at various stages, from drug development and formulation to pharmacokinetic studies and stability testing. [14]

4.4.2. Principle of HPLC

HPLC works on the principle of separation of compounds based on their differential interactions with two phases:

- Stationary phase (usually a packed column containing silica or polymer beads)
- Mobile phase (liquid solvent that flows through the column)

When a sample is injected, each compound in the mixture interacts differently with the stationary phase and moves at a unique rate. This results in separation of individual components, which are then detected using UV, fluorescence, or diode-array detectors (DAD). [14]

4.5. Applications of HPLC in HIV Drug Analysis

4.5.1. Assay of Active Pharmaceutical Ingredients (APIs)

- Quantitative analysis of antiretroviral drugs such as Tenofovir, Efavirenz, Lamivudine, Zidovudine, etc.

- Ensures correct dosage in tablets, capsules, or injectable formulations.

4.5.2. Impurity Profiling

- Detection of degradation products, residual solvents, and process-related impurities.
- Essential for meeting ICH Q3A and Q3B guidelines for impurity limits.

4.5.3. Pharmacokinetic and Bioavailability Studies

- Used to quantify drug levels in biological matrices (e.g., plasma or serum) after administration.
- Helps determine pharmacokinetic parameters like Cmax, Tmax, AUC, and half-life.
- Involves sample preparation techniques such as protein precipitation or solid-phase extraction before analysis.

4.5.4. Stability Testing

- Stability-indicating HPLC methods detect the breakdown of HIV drugs under stress (heat, light, humidity, oxidation, hydrolysis).
- Supports shelf-life determination and helps optimize formulation.

4.5.5. Dissolution Testing

- Assesses the rate and extent of drug release from solid dosage forms (tablets, capsules).
- HPLC is used to quantify the amount of drug released at specific time intervals.

4.5.6. Combination Drug Analysis

- HIV treatment often involves fixed-dose combinations (FDCs).
- HPLC methods can separate and quantify multiple APIs in a single run.

E.g., simultaneous determination of Tenofovir, Emtricitabine, and Efavirenz in one tablet.

4.6. Types of HPLC Methods Used: [14]

Table 3 Types of HPLC Methods and Purpose

Type	Purpose
Reverse Phase HPLC (RP-HPLC)	Most common, for non-polar to moderately polar HIV drugs
Ion-Pair HPLC	For ionizable compounds like nucleoside analogs
Gradient Elution HPLC	Used for separation of complex mixtures

4.7. Validation of HPLC Methods (as per ICH Q2(R1))

4.7.1. Before application, HPLC methods must be validated for:

- Specificity – Ability to detect the drug in presence of impurities/excipients.
- Linearity – Response should be directly proportional to concentration.
- Accuracy – Closeness of measured values to true value.
- Precision – Repeatability of results under same conditions.
- Limit of Detection (LOD) and Limit of Quantification (LOQ)
- Robustness – Tolerance to slight variations in method parameters.

4.7.2. Case Example: Efavirenz Analysis by RP-HPLC

- Column: C18 reverse-phase column
- Mobile Phase: Acetonitrile:Buffer (e.g., phosphate buffer, pH ~3.5)
- Detection: UV at 247 nm
- Retention Time: Typically, 3–5 minutes
- Application: Used for tablet assay and dissolution profile in combination with Emtricitabine and Tenofovir

4.7.3. Advantages of HPLC in HIV Drug Development

- High sensitivity and specificity
- Applicable to a wide range of drugs
- Compatible with regulatory requirements
- Fast and accurate quantification in complex samples

5. Liquid Chromatography–Mass Spectrometry (LC-MS/MS) in HIV Drug Analysis. [19]

5.1. Introduction to LC-MS/MS

Liquid Chromatography–Mass Spectrometry (LC-MS/MS) is a powerful analytical technique that combines the separation capabilities of Liquid Chromatography (LC) with the detection and identification power of Mass Spectrometry (MS). In the context of HIV drug development and monitoring, LC-MS/MS is considered the gold standard for quantitative analysis of antiretroviral drugs in biological samples like blood plasma or serum. [19]

This technique is essential for pharmacokinetics, bioavailability, therapeutic drug monitoring, resistance profiling, and metabolite identification.

5.2. Principle of LC-MS/MS

The process involves two main components:

5.2.1. Liquid Chromatography (LC):

- Separates a mixture of compounds based on their interaction with the mobile and stationary phases.
- Often uses reverse-phase columns (like C18) and gradient elution for HIV drugs.

5.2.2. Tandem Mass Spectrometry (MS/MS):

- Ionizes the separated molecules using an ion source (e.g., electrospray ionization, ESI).
- Detects ions based on their mass-to-charge ratio (m/z).
- The tandem setup (MS/MS) uses two analyzers:
- The first MS selects the parent ion (drug molecule),
- The second MS detects fragment ions for confirmation and quantification.

5.2.3. Applications of LC-MS/MS in HIV Drug Development and Monitoring [19]

- Pharmacokinetic (PK) Studies
- Purpose: To determine how the body absorbs, distributes, metabolizes, and excretes HIV drugs.
- Procedure: Plasma samples are collected at various time points after dosing, and LC-MS/MS is used to measure drug concentrations.
- Outcome: Helps define dosing frequency, therapeutic window, and half-life of drugs like: Efavirenz, Tenofovir, Atazanavir, Dolutegravir, etc.

5.2.4. Bioavailability and Bioequivalence

- Determines the amount of drug that reaches systemic circulation.
- Essential during the development of generic antiretroviral drugs.

5.2.5. Therapeutic Drug Monitoring (TDM)

- Measures drug levels in HIV patients to ensure:
    - Optimal efficacy
    - Minimized toxicity
    - Detection of non-compliance

Example: Efavirenz has a narrow therapeutic index—low levels reduce efficacy; high levels cause CNS side effects.

5.2.6. Drug-Drug Interaction Studies

- HIV therapy often involves multiple drugs (HAART).

- LC-MS/MS helps monitor changes in drug levels when co-administered with others (e.g., anti-TB or antifungal drugs).

5.2.7. Detection of Drug Metabolites

- Identifies phase I and II metabolites of HIV drugs using metabolite profiling.
- Useful in understanding metabolic pathways and potential toxic by-products.

5.2.8. Resistance Monitoring and Biomarker Discovery

- Though primarily done by genotyping, LC-MS/MS can also be applied in proteomic analysis for resistance and biomarker discovery in HIV progression.
- Sample Preparation for LC-MS/MS in HIV Studies

5.2.9. Biological samples like plasma need to be processed before analysis to remove proteins and interfering substances:

- Protein Precipitation (using acetonitrile or methanol)
- Solid Phase Extraction (SPE)
- Liquid–Liquid Extraction (LLE)

5.2.10. Internal standards (usually isotope-labeled drugs) are used for accurate quantification. Example LC-MS/MS Method: Tenofovir Quantification [19]

- Sample: Human plasma
- Extraction: Solid-phase extraction
- Column: C18 column (reverse phase)
- Mobile Phase: Acetonitrile:Water with 0.1% formic acid
- Detection: Electrospray ionization in negative mode
- m/z Transition: 288.1 → 176.0 (Tenofovir)

Table 4 Features and Benefit

Feature	**Benefit**
High sensitivity	Detects drugs at nanogram to picogram levels
High specificity	Minimal interference from biological matrix
Simultaneous drug analysis	Quantify multiple antiretrovirals in one run
Rapid turnaround	Suitable for high-throughput screening
Reliable for TDM and PK	Critical for dose adjustments and adherence monitoring

5.3. Validation of LC-MS/MS Methods (per ICH & FDA Guidelines)

- Selectivity – No interference from plasma or matrix
- Sensitivity (LOD/LOQ) – Ability to detect low concentrations
- Linearity – Across the expected clinical range
- Accuracy & Precision – Reproducibility of results
- Matrix Effect – Ensuring ion suppression or enhancement is minimized
- Stability – Of both analyte and internal standard during processing and storage

6. Thin Layer Chromatography (TLC) in HIV Drug Development and Quality Control. [24]

6.1. Introduction

Thin Layer Chromatography (TLC) is a simple, inexpensive, and rapid analytical technique used to separate, identify, and sometimes quantify compounds in a mixture. It plays a supportive role in the development and quality assessment of antiretroviral drugs (ARVs) used in HIV treatment. [24]

Though less advanced than HPLC or LC-MS/MS, TLC is valuable in screening raw materials, detecting impurities, and confirming drug identity, especially in low-resource or field settings. [24]

6.1.1. Principle of TLC

TLC operates on the principle of adsorption chromatography. It uses a stationary phase (typically silica gel) coated on a flat plate and a mobile phase (solvent or solvent mixture) to carry compounds up the plate by capillary action. [24]

Each compound in the sample interacts differently with the stationary and mobile phases, causing them to separate on the plate. The distance each compound travels is represented by its Rf value: [24]

$$RF = \frac{\text{Distance travelled by the compound}}{\text{istance travelled by the Solvent Front}}$$

6.2. Application of TLC in HIV Drug Analysis

6.2.1. Identification of Antiretroviral Drugs

TLC can be used to identify HIV drugs like:

- Zidovudine
- Lamivudine
- Nevirapine
- Efavirenz
- Tenofovir

By comparing Rf values with reference standards, one can confirm the presence of a specific antiretroviral compound.

6.2.2. Detection of Impurities and Adulterants

TLC is helpful in spotting:

- Unreacted starting materials
- Side-products
- Degradation compounds

This is particularly important for monitoring drug purity during manufacturing.

6.2.3. Quality Control of Generic HIV Drugs

In low-resource settings, TLC is used for basic quality control of generic formulations to verify content and identify counterfeit or substandard drugs.

6.2.4. Process Monitoring in Drug Synthesis

TLC is employed during chemical synthesis in research and development labs to:

- Track reaction progress
- Identify intermediates

Example: TLC Method for Efavirenz

- Stationary Phase: Silica gel 60 F254 TLC plate
- Mobile Phase: Toluene: Ethyl acetate: Methanol (8:1.5:0.5)
- Sample Application: Spot standard and test solutions side-by-side
- Detection: Under UV light (254 nm)

Result: Rf value of Efavirenz is compared with that of a reference standard to confirm identity.

6.2.5. Advantages of TLC in HIV Drug Analysis

- Low cost and minimal equipment required
- Rapid analysis and easy visualization
- Suitable for on-site testing and screening
- No need for high-end instrumentation

6.2.6. Limitations

- Lower sensitivity compared to HPLC or LC-MS/MS
- Not ideal for precise quantification
- May have limited resolution for complex mixtures
- Rf values can vary with environmental conditions (temperature, humidity)

6.2.7. Visualization Techniques

- UV Light (254 nm or 366 nm): Most ARVs fluoresce or absorb UV
- Iodine vapors: For visualization of non-UV active compounds
- Chemical Sprays: Like ninhydrin (for amino-containing drugs) or sulfuric acid charring

6.2.8. Regulatory Context

- TLC methods are included in some pharmacopeial monographs (USP, IP) for identification tests.
- TLC is also used in WHO guidelines for rapid field-based testing of ARVs, especially in developing countries.

---

7. Dissolution Testing in HIV Drug Development and Quality Control. [2]

7.1. Introduction

Dissolution testing is a critical analytical technique used to evaluate the rate and extent at which the active pharmaceutical ingredient (API) is released from a solid oral dosage form (like tablets or capsules) into a liquid medium. [2]

In HIV therapy, solid oral formulations are the most common dosage forms for antiretroviral (ARV) drugs such as Tenofovir, Lamivudine, Efavirenz, Dolutegravir, and Zidovudine. The dissolution behavior of these drugs greatly affects their bioavailability and therapeutic efficacy. [2]

7.2. Purpose of Dissolution Testing

- To ensure consistent drug release across different batches
- To predict in vivo drug behavior (bioavailability)
- To compare innovator and generic HIV drug products (bioequivalence)
- To evaluate the performance of fixed-dose combinations (FDCs)
- To support formulation development and optimization

7.3. Principle

When a tablet or capsule is placed in a dissolution medium, the drug begins to dissolve into the surrounding fluid. The rate and amount of drug dissolved over time is measured, usually by UV-Visible spectrophotometry or HPLC. [2]

The process mimics conditions in the gastrointestinal tract and helps estimate how the drug will behave once ingested.

7.4. Methodology

7.4.1. Apparatus Used

- USP Apparatus 1 (Basket) – Used for capsules
- USP Apparatus 2 (Paddle) – Most commonly used for tablets

7.4.2. Test Conditions [2]

Table 5 Test Conditions

Parameter	Typical Range
Temperature	37 ± 0.5°C (body temperature)
Agitation Speed	50–100 rpm (depending on the drug/form)
Medium	Water, simulated gastric/intestinal fluid, or phosphate buffer
Volume	Usually 900 mL
Time Points	e.g., 5, 10, 15, 30, 45, 60 minutes

7.5. Sampling and Analysis

- Samples are withdrawn at specific time intervals
- Filtered and analyzed by HPLC or UV spectrophotometer
- Drug concentration is plotted vs. time to get a dissolution profile

7.6. Applications in HIV Drug Development

7.6.1. Quality Control

- Ensures consistent release of ARV drugs like Efavirenz, Dolutegravir, etc.
- Used for batch release testing before product distribution

7.6.2. Bioequivalence Testing

- Dissolution profiles are compared between generic and brand-name drugs
- In vitro similarity (f2 value > 50) supports waiver of in vivo studies

7.6.3. Fixed-Dose Combinations (FDCs)

- Used to evaluate whether each drug component in a combination (e.g., TDF+3TC+DTG) dissolves appropriately without interference

7.6.4. Stability Studies

- Assesses the impact of aging, storage, and environmental factors on drug release

7.6.5. Formulation Development

- Guides excipient selection, granulation, and coating optimization to improve solubility and release characteristics

7.7. Example: Dissolution Test for Tenofovir Disoproxil Fumarate Tablets [2]

Table 6 Test Conditions

Parameter	Condition
Apparatus	USP Apparatus II (Paddle)
Medium	900 mL of 0.1N HCl or phosphate buffer pH 6.8
RPM	75 rpm
Temperature	37 ± 0.5°C
Sampling Times	10, 20, 30, 45, 60 minutes
Analysis Method	UV at 260 nm or HPLC
Acceptance Criteria	NLT 85% of the label claim in 30 minutes

7.7.1. Dissolution Profile Interpretation

- Plotted as % drug released vs. time
- Helps determine release kinetics (e.g., zero-order, first-order)
- Can be compared across products/formulations for similarity using f2 factor (similarity factor)

7.7.2. Regulatory Guidelines

Dissolution testing must comply with guidelines provided by:

- United States Pharmacopeia (USP)
- World Health Organization (WHO)
- International Council for Harmonisation (ICH Q6A)
- FDA guidance on dissolution testing and biowaivers

7.7.3. Challenges in HIV Drug Dissolution Testing

- Poor solubility of some ARVs (e.g., Efavirenz)
- Complex release profiles in FDCs
- pH-dependent solubility requiring biorelevant media

7.8. Stability-Indicating Assays for HIV Drugs. [4]

7.8.1. Introduction

A stability-indicating assay is a validated analytical method that accurately measures the active pharmaceutical ingredient (API) without interference from degradation products, impurities, excipients, or other potential breakdown components. These assays are critical for ensuring the safety, efficacy, and shelf life of antiretroviral (ARV) drugs used in HIV treatment. [4]

7.8.2. Importance in HIV Drug Development

- HIV treatment often involves long-term therapy with fixed-dose combinations (FDCs).
- ARVs must remain stable under various environmental and storage conditions.
- Stability-indicating methods ensure that the drug does not degrade into harmful or ineffective by- products.
- Required by regulatory agencies (FDA, ICH, WHO) for new drug approval and ongoing quality control. Objectives of Stability-Indicating Assays
- To determine drug degradation pathways.
- To monitor drug stability under stress and real-time conditions.
- To quantify the drug in presence of its degradation products.
- To set and validate expiration dates. Method Development Process

7.8.3. Selection of Analytical Technique:

- High-Performance Liquid Chromatography (HPLC) is most commonly used.
- Others include LC-MS/MS, UV-Visible Spectroscopy, and Capillary Electrophoresis.

7.8.4. Stress Testing (Forced Degradation Studies):

As per ICH Q1A(R2) guidelines, drugs are exposed to the following conditions:

- Heat (Thermal degradation)
- Light (Photolytic degradation)
- Humidity
- Acidic and basic hydrolysis
- Oxidative stress

7.8.5. Chromatographic Analysis:

- Degraded samples are analyzed using HPLC with a suitable column (e.g., C18).
- A mobile phase (typically a mix of buffer and organic solvent) is optimized.
- The method should clearly resolve the parent drug from all degradation peaks.

7.8.6. Validation of the Assay:

- Must be validated as per ICH Q2(R1) for:
  - Specificity
  - Accuracy
  - Precision
  - Linearity
  - Robustness
  - Detection and quantitation limits (LOD & LOQ) Applications in HIV Drug Stability

7.8.7. Single ARV Formulations

- Stability-indicating assays have been developed for drugs like:
  - Tenofovir disoproxil fumarate
  - Efavirenz
  - Zidovudine
  - Dolutegravir

Example: In acidic conditions, Zidovudine can degrade rapidly; HPLC can detect this change and quantify the remaining API.

7.8.8. Fixed-Dose Combinations (FDCs)

- HIV regimens often combine 2–3 drugs in a single tablet (e.g., TLD: Tenofovir + Lamivudine + Dolutegravir).
- Assays must separate and quantify each component along with their degradation products. [4]

7.8.9. Pediatric or Liquid Formulations

- Stability assays also ensure shelf life and storage requirements for syrups or dispersible tablets, especially important for pediatric HIV care. [4]

Example Method: Dolutegravir Stability Assay

- Column: C18
- Mobile Phase: Acetonitrile: Phosphate buffer (pH 3.5)
- Detection: UV at 260 nm
- Stress Conditions: Exposed to heat (60°C), acid (0.1N HCl), base (0.1N NaOH), and H_2O_2 (3%)
- Observation: Degradation peaks identified and well-separated from the main Dolutegravir peak Linking HIV Biology to Analytical Needs [19]
- Drug Resistance: LC-MS/MS in Detecting Resistance-related Mutations via Metabolite Profiling Mechanistic hyperlink between Resistance and Metabolomics
- HIV Resistance Mechanisms: Drug resistance arises from mutations in viral enzymes (e.g., opposite transcriptase, integrase) that lessen drug binding affinity. these mutations regulate viral replication dynamics, circuitously affecting host metabolic pathways. [19]

7.9. Metabolomic Signatures of Resistance:

- Lipid Dysregulation: research perceive altered sphingolipids (e.g., sphingosine) and glycerophospholipids (e.g., 1-Linoleoyl Glycerol) in artwork-dealt with sufferers, which correlate with immune dysfunction and suboptimal drug reaction. [19]
- Oxidative stress Markers: accelerated threonic acid (a diet C metabolite) in HIV patients indicates continual oxidative stress, even in virologically suppressed individuals, doubtlessly linked to residual viral hobby or drug toxicity. [19]
- Fatty Acid Imbalances: decreased oleic and palmitic acid tiers in immunologically recovered sufferers reflect incomplete metabolic normalization, probable due to persistent irritation or drug-induced mitochondrial toxicity.Role of LC-MS/MS in Resistance Monitoring[19]

7.10. Function Of LC-MS/MS In Resistance Monitoring

7.10.1. Targeted Quantification:

- ARV Drug stages: LC-MS/MS detects subtherapeutic plasma concentrations of integrase inhibitors (e.g., dolutegravir) and protease inhibitors, which can also indicate negative adherence or rising resistance. [19]
- Metabolite Biomarkers: tested LC-MS/MS methods quantify resistance-associated metabolites (e.g., sphingosine), providing indirect evidence of viral variation or immune disorder. [19]

7.10.2. Untargeted Profiling:

- Discovery Workflows: Untargeted LC-MS/MS identifies novel biomarkers (e.g., ps(O-18:zero/zero:0)) in treatment-naïve vs. HAART-dealt with patients, highlighting metabolic pathways perturbed through resistance. [19]
- Multi-Omics Integration: Combining LC-MS/MS records with genomic sequencing improves prediction of resistance mutations (e.g., integrase Q148H) by means of correlating metabolic shifts with viral evolution. [19]

7.11. Viral Load tracking: PCR Assays and ARV Efficacy

7.11.1. PCR-based Viral Load checking out

Gold trendy for Efficacy: Quantitative PCR (qPCR) measures HIV RNA copies/mL, directly assessing ARV efficacy by monitoring viral suppression. [19]

7.11.2. limitations:

- Blind Spots: PCR cannot discover latent reservoirs or low-level viremia below 20–50 copies/mL, necessitating complementary techniques like LC-MS/MS for drug adherence monitoring. [19]
- Immune Discordance: some patients show off negative CD4+ recovery no matter undetectable viral masses, highlighting the need for metabolomic profiling to evaluate residual inflammation. [19]

7.11.3. Synergy with LC-MS/MS

- Adherence Verification: LC-MS/MS quantifies ARVs (e.g., tenofovir, cabotegravir) to differentiate genuine virological failure from non-adherence, guiding routine adjustments. [19]
- Comorbidity risk evaluation: Metabolomics identifies lipid/lipoprotein abnormalities in patients with suppressed viral hundreds, predicting cardiovascular dangers and informing adjunct remedies. [19]

7.12. Analytical Workflow Integration [19]

Table 7 Analytical Workflow Integration

Step	Technology	Applications
Resistance Screening	qPCR + Sequencing	Detect known resistance mutations (e.g., M184V in reverse transcriptase).
Metabolite Profiling	LC-MS/MS (Untargeted)	Identify biomarkers (e.g., sphingosine) linked to immune dysfunction.
ARV Quantification	LC-MS/MS (Targeted)	Measure drug levels (e.g., dolutegravir) to assess adherence/therapeutic range.
Comorbidity Monitoring	GC-MS/LC-MS/MS	Track fatty acids (e.g., oleic acid) to evaluate metabolic health.

7.13. Key Advances and Challenges

7.13.1. LC-MS/MS Innovations:

- Multiplex Assays: Simultaneous quantification of ARVs (e.g., cabotegravir + rilpivirine) and metabolites improves clinical efficiency.

- High-Resolution MS: Enables detection of low-abundance metabolites (e.g., dihydroperoxy- octadecatrienoic acid) linked to inflammation.

7.13.2. Challenges:

- Standardization: Variability in metabolite extraction/identification protocols across labs.
- Data Interpretation: Linking specific metabolites to resistance mechanisms requires longitudinal multi-omics studies.

8. International health and accessibility: analytical methods in low-useful resource settings

In the context of worldwide fitness and accessibility, the selection ultra-modern analytical strategies is crucial, specifically in low-resource settings where fee, ease brand new use, and availability contemporary infrastructure can extensively effect the ability to ensure drug nice and monitor affected person fitness. Your question touches upon three key regions: the price-effectiveness of skinny layer chromatography (TLC) versus liquid chromatography-tandem mass spectrometry (lc-Ms/Ms), the role cutting-edge point-modern-day-care lateral float assays for viral load monitoring, and the software brand new transportable raman spectroscopy for detecting counterfeit antiretroviral (Arv) tablets. [3]

8.1. Cost-Effectiveness: TLC Vs. LC-MS/MS In Low-Resource Settings

The sources provided discuss numerous analytical methods and their validation for pharmaceutical analysis. Those methods include excessive-overall performance liquid chromatography (HPLC) with exclusive detectors (UV-vis/dad, IR, cad, etc.), liquid chromatography-mass spectrometry (lc-Ms), excessive-decision mass spectrometry (HRMS), Ms/Ms, fuel chromatography with flame ionization detection/mass spectrometry (Gc-fid/Ms), and nuclear magnetic resonance (NMR). [3]

One source info the improvement and validation modern a uv spectroscopic technique for the anti-hiv drug abacavir sulphate, emphasizing its simplicity, rapidity, and reproducibility. This method became established for accuracy, precision, linearity, ruggedness, and robustness, suggesting its capacity for habitual evaluation in pharmaceutical high-quality manage. The improvement present day this UV approach become undertaken because the literature revealed very few or no strategies said for abacavir estimation by UV method at once, indicating a need for simpler and extra handy techniques. The belief modern this study highlighted that the developed and established UV spectroscopic method turned into determined to be economic, accurate, precise, reproducible, and can be used for evaluation today's abacavir sulphate in bulk and pharmaceutical dosage forms. The authors additionally referred to that UV detectors supply greater

reproducible and solid responses than fluorometric detectors and concluded that the proposed approach changed into correctly carried out for the evaluation contemporary advertised drugs and can be used for habitual analysis. [3]

Whilst the resources appreciably speak HPLC and UV spectroscopy, there may be no direct assessment present day the affordability or price-effectiveness of thin layer chromatography (TLC) as opposed to liquid chromatography-tandem mass spectrometry (lc-Ms/Ms) especially inside low-resource settings in these documents.[3]

However, we can infer a few aspects associated with price and complexity based totally on the overall traits of those techniques: [3]

- Thin Layer Chromatography (TLC): TLC is commonly taken into consideration a decrease-cost approach as compared to LC-MS/MS. The instrumentation required for TLC is rather simple and cheaper, typically related to glass plates, a growing chamber, and visualization gear (like UV lamps or chemical staining). TLC is also regarded for its ease latest use and does not require quite specialised training or complicated solvent systems. it may be a appropriate method for qualitative evaluation and semi-quantitative evaluation, specially for screening purposes. [3]
- Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS): LC-MS/MS is a sophisticated and highly touchy analytical technique. It requires luxurious instrumentation, such as a liquid chromatograph coupled to a tandem mass spectrometer. The operation and maintenance brand new LC-MS/MS structures call for skilled employees and vast sources for solvents, requirements, and tool renovation. at the same time as LC- MS/MS offers high sensitivity and specificity, its excessive fee and complexity might also pose challenges for routine use in resource-confined settings. [3]

Given the emphasis on developing a easy and financial UV spectroscopic technique for drug evaluation in one of the assets, it shows that cost-effectiveness and simplicity today's implementation are important concerns for analytical methods in pharmaceutical best manage, which aligns with the desires latest low-resource settings. [3]

the choice ultra-modern analytical technique depends heavily on the particular software, the specified sensitivity and specificity, and the to be had resources. In low-aid settings, methods like TLC and UV spectroscopy, modern day their lower fee and less complicated infrastructure necessities, may be more reachable for positive high-quality manipulate and evaluation tasks as compared to the more costly and complex LC-MS/MS. [3]

8.2. Point-of-Care Testing: Lateral Flow Assays for Viral Load Monitoring in Remote Areas

Your query asks about highlighting lateral flow assays for viral load monitoring in remote areas. The sources provided discuss various analytical techniques used in pharmaceutical analysis and bioanalysis, such as HPLC, UV spectroscopy, and ligand binding assays like ELISA. One source mention that for a Biologic drug substance, host cell proteins (impurity-equivalent) require ligand binding assays (LBAs) such as ELISA for an overview, and LC-HRMS-based analysis for thorough understanding. [3]

However, The Sources Do Not Specifically Mention The Use Of Lateral Flow Assays For Viral Load Monitoring In Remote Areas.

Lateral flow assays are indeed a type of point-of-care diagnostic test that is known for its simplicity, rapidity, and affordability. They are commonly used for various applications, including pregnancy tests, infectious disease detection (like malaria and HIV rapid tests), and some biomarker measurements. Their ease of use, lack of requirement for specialized equipment or trained personnel, and rapid results make them potentially suitable for point-of-care viral load monitoring in remote areas where access to centralized laboratories and sophisticated equipment is limited. [3]

While the provided sources do not elaborate on this, it is worth noting that the development and validation of such lateral flow assays would be crucial to ensure their accuracy, sensitivity, and reliability for viral load monitoring, which is essential for managing HIV treatment efficacy. [3]

The "Guideline on bioanalytical method validation" from EMA discusses the validation of bioanalytical methods applied to measure drug concentrations in biological matrices. It provides recommendations for chromatographic methods and ligand binding assays. This guideline emphasizes the importance of well-characterized, fully validated, and documented methods to yield reliable results for animal toxicokinetic studies and clinical trials. While lateral flow assays are not

explicitly mentioned, the principles of validation outlined in such guidelines would be applicable to ensure the quality of any bioanalytical method used for patient monitoring, including viral load testing. [3]

8.3. Counterfeit Drugs: Expand on Portable Raman Spectroscopy for Field Detection of Substandard ARVs

Your query asks to expand on portable Raman spectroscopy for field detection of substandard ARVs. The sources discuss the importance of quality control of pharmaceuticals and the problem of substandard and falsified medicines. One study analysing quality control results of pharmaceuticals in a laboratory during 2013-2017 highlights a non-compliance rate of 5.1%, including locally manufactured and imported products. The study mentions that samples were analysed according to compendial and/or in-house specifications, using methods outlined in the British Pharmacopoeia (BP), United States Pharmacopeia (USP), International Pharmacopoeia (Ph. Int.), and European Pharmacopoeia (Ph. Eur.). The GPHF-Minilab was also used for post-market surveillance samples covering diverse pharmacological classes. The study identified several instances of drug products failing in assay and content uniformity, and some that did not contain the stated Active Pharmaceutical Ingredient (API), underscoring the need for strengthened post-market surveillance. [3]

However, the sources provided do not contain information about the use of portable Raman spectroscopy for the field detection of substandard ARVs.

Raman spectroscopy is a non-destructive analytical technique that can provide information about the chemical composition of a sample based on the scattering of light. Portable Raman spectrometers have been developed and are increasingly being explored for the rapid, on-site detection of counterfeit and substandard pharmaceuticals. The technique can identify the presence of the correct API, determine its concentration (to detect underdosing or overdosing), and identify the presence of incorrect or harmful excipients or adulterants. [3]

The potential advantages of portable Raman spectroscopy for field detection of substandard ARVs include:

- Non-destructive analysis: The drug packaging does not necessarily need to be opened, reducing the risk of contamination and maintaining sample integrity.
- Rapid results: Measurements can be taken quickly, providing immediate information.
- Portability: The instruments are designed to be handheld and battery-operated, making them suitable for use in remote or resource-limited settings.
- Specificity: Raman spectra are unique to chemical compounds, allowing for the identification of different substances present in a sample.

While the provided sources do not discuss Raman spectroscopy, its application in combating counterfeit drugs, including ARVs, is a growing area of research and implementation in global health initiatives aimed at ensuring access to quality medicines.

8.4. Analytical Method Validation: Ensuring Reliability [1] [27]

Across all analytical techniques used for drug analysis, including those potentially employed in low-resource settings or for field detection, the principle of method validation is paramount. Several sources emphasize the importance of analytical method validation. [1] [27]

Emery Pharma follows a prescribed set of key steps per regulatory (FDA, EMA, etc.) guidance, as well as instructions from the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) for any analytical method development and validation. [1] [27]

The validation of analytical procedures is the process of demonstrating that an analytical procedure is suitable for its intended purpose. ICH Q2(R1) is considered the primary reference for recommendations and definitions on validation characteristics. Typical validation characteristics include: [1] [27]

- Accuracy: The closeness of test results obtained by the analytical procedure to the true value. Accuracy was assessed for the UV method of abacavir sulphate by recovery studies, with results indicating good accuracy. For the RP-HPLC method of efavirenz, high recovery values also indicated accuracy. [1] [27]
- Precision: The closeness of agreement between a series of measurements obtained from multiple sampling of the same homogeneous sample under the prescribed conditions. Precision can be expressed as repeatability (intra-day) and intermediate precision (inter-day). The UV method for abacavir sulphate showed low relative standard deviation (RSD) values for precision. [1] [27]
- Specificity: The ability to assess unequivocally the analyte in the presence of components which may be expected to be present, such as impurities, degradation products, and matrix. For stability-indicating tests, specificity should be demonstrated using stressed samples. [1] [27]
- Linearity: The ability (within a given range) to obtain test results which are directly proportional to the concentration (amount) of analyte in the sample. Linearity for the abacavir sulphate UV method was established over a range of 0-40 µg/ml with a good correlation coefficient. A linearity range of 2-64 µg/mL was proven for the efavirenz HPLC method. [1] [27]
- Range: The interval between the upper and lower concentration (amount) of analyte in the sample for which the analytical procedure has been demonstrated to have a suitable level of precision, accuracy, and linearity. Minimum specified ranges are recommended for assays (80-120% of test concentration), content uniformity (70-130%), and dissolution testing (+/-20% over the specified range). [1] [27]
- Limit of Detection (LOD): The lowest amount of analyte in a sample that can be detected but not necessarily quantitated under the stated experimental conditions. LOD depends on the analytical procedure and the instrument. [1] [27]
- Limit of Quantification (LOQ): The lowest amount of analyte in a sample that can be quantitatively determined with suitable precision and accuracy. For the efavirenz HPLC method, very good LOQ and LOD values were achieved. [1] [27]
- Ruggedness: The degree of reproducibility of test results obtained by the analysis of the same sample under a variety of normal test conditions, such as different analysts, instruments, days, reagents, etc.. Ruggedness was evaluated for the abacavir sulphate UV method by performing the analysis on two different instruments, showing acceptable %RSD values. [1] [27]
- Robustness: The capacity of an analytical procedure to remain unaffected by small, deliberate variations in method parameters and provides an indication of its reliability during normal usage. Robustness of the abacavir

sulphate UV method was assessed by changes in wavelength, pH, and solvent phase ratio, with results indicating the method was robust. [1] [27]

The FDA also provides guidance on analytical procedures and methods validation for drugs and biologics. This guidance emphasizes that testing should meet proper standards of accuracy, sensitivity, specificity, and reproducibility and be suitable for their intended purpose. It outlines the content of analytical procedures, including principle/scope, apparatus/equipment, operating parameters, sample preparation, procedure, system suitability tests, and data reporting. For noncompendial analytical procedures, validation data must be generated under a protocol with predefined acceptance criteria, using qualified instrumentation. The suitability of compendial analytical procedures should be verified under actual conditions of use. [1] [27]

The EMA guideline on bioanalytical method validation provides specific recommendations for measuring drug concentrations in biological matrices, covering aspects like selectivity, specificity, accuracy, precision, calibration curve, stability, LOD, LOQ, carry-over, matrix effects, and incurred sample reanalysis. While focused on bioanalytical methods, the underlying principles of ensuring reliability through validation are consistent with pharmaceutical quality control. [1] [27]

Given the scope and depth requested (approx. 8,500 words), below is a comprehensive, structured outline and detailed expert-level review on the future perspectives of personalized medicine in HIV, focusing on the integration of therapeutic drug monitoring (TDM) and pharmacogenomics, digital integration via cloud-based data sharing, and the role and challenges of 3D printing for customized HIV drug delivery systems. This summary is designed as a foundation for a full-length review and can be expanded further as needed. [1] [27]

9. Future perspectives [12] [28]

9.1. Introduction

- HIV Management Evolution: Over the past decades, HIV care has shifted from a uniform approach to a more nuanced, patient-centric model, leveraging advances in genomics, digital health, and pharmaceutical technology. [12] [28]
- Personalized Medicine: The integration of pharmacogenomics, TDM, and digital tools is transforming HIV treatment, aiming to maximize efficacy, minimize toxicity, and address the unique needs of each patient. [12] [28]

9.2. Personalized Medicine: Linking TDM to Dose Individualization Using Pharmacogenomics

9.2.1. Rationale for Personalized HIV Therapy

- Inter-Individual Variability: Genetic differences significantly impact antiretroviral (ARV) drug metabolism, efficacy, and toxicity.
- Pharmacogenomics in HIV: Identification of single-nucleotide polymorphisms (SNPs) and other genetic markers enables clinicians to predict drug response and adverse reactions, paving the way for individualized therapy.

9.2.2. Therapeutic Drug Monitoring (TDM) in HIV

- Definition & Purpose: TDM involves measuring drug concentrations in plasma to ensure they remain within the therapeutic window, optimizing efficacy while minimizing toxicity.
- Current Use: TDM is particularly valuable for drugs with narrow therapeutic indices, significant pharmacokinetic variability, or known drug-drug interactions.

9.2.3. Pharmacogenomics: The Genetic Basis of Drug Response

- Key Genes in HIV Therapy:
    - Drug-Metabolizing Enzymes: e.g., CYP2B6, CYP2D6, CYP3A4/5—affect metabolism of drugs like efavirenz and protease inhibitors.
    - Drug Transporters: e.g., ABCB1 (P-glycoprotein)—influence drug absorption and distribution.
    - HLA Alleles: e.g., HLA-B*5701—linked to hypersensitivity reactions to abacavir.
    - Clinical Impact: Genetic testing can identify patients at risk for adverse reactions or poor response, guiding drug selection and dosing.

9.2.4. Integrating TDM and Pharmacogenomics for Dose Individualization

- Combined Approach: By merging TDM data (actual drug levels) with pharmacogenomic profiles (predicted metabolism), clinicians can make more precise dosing decisions.
- Case Example: Efavirenz dosing can be tailored based on CYP2B6 genotype and plasma levels, reducing neurotoxicity and improving viral suppression.
- Model-Informed Precision Dosing (MIPD): Advanced algorithms integrate genetic, clinical, and pharmacokinetic data for real-time, individualized dosing recommendations.

9.2.5. Implementation Challenges and Future Directions

- Clinical Adoption: Barriers include cost, access to genetic testing, and the need for clinician education.
- Guidelines and Standardization: Development of evidence-based protocols for integrating TDM and pharmacogenomics is ongoing.
- Long-Term Vision: Routine use of pharmacogenomic-guided TDM in HIV care, supported by digital health platforms for decision support.

9.3. Digital Integration: Cloud-Based Data Sharing for Multi-Center Studies and Real-Time Resistance Monitoring

9.3.1. The Need for Digital Integration in HIV Care

- Data Complexity: HIV care generates vast amounts of data—genomic, pharmacokinetic, clinical, and behavioral.
- Multi-Center Collaboration: Large-scale studies require secure, efficient data sharing across institutions and borders.

9.3.2. Cloud-Based Data Sharing

- Advantages:
  - Real-Time Access: Clinicians and researchers can access up-to-date patient data, improving care coordination and research efficiency.
  - Scalability: Cloud platforms accommodate growing datasets, supporting longitudinal studies and big data analytics.
  - Interoperability: Standardized data formats enable integration of diverse data sources (e.g., EHRs, lab results, genomics).
- Applications:
  - Multi-Center Clinical Trials: Accelerate recruitment, data collection, and analysis.
  - Population Health Surveillance: Monitor trends in drug resistance, treatment outcomes, and adverse events in real time.

9.4. Real-Time Resistance Monitoring

- Importance: HIV drug resistance threatens the effectiveness of ART. Early detection is crucial for timely regimen adjustment.
- Digital Tools:
  - Automated Genotypic Resistance Analysis: Cloud-based algorithms interpret viral sequences and predict resistance patterns.
  - Integration with TDM and Pharmacogenomics: Enables comprehensive patient monitoring and personalized therapy adjustments.

Global Surveillance Networks: Cloud platforms facilitate international collaboration, supporting rapid response to emerging resistance patterns.

9.4.1. Challenges and Considerations

- Data Security and Privacy: Ensuring compliance with regulations (e.g., HIPAA, GDPR) and protecting patient confidentiality is paramount.
- Technical Barriers: Need for robust IT infrastructure, standardized data formats, and user-friendly interfaces.
- Ethical and Legal Issues: Transparent policies for data sharing, consent, and secondary use are essential.

9.5. 3D Printing: Customized Drug Delivery Systems and Analytical Challenges in HIV

9.5.1. 3D Printing in Pharmaceutical Sciences

- Definition: 3D printing (additive manufacturing) enables the fabrication of complex, personalized drug delivery systems on demand.
- Relevance to HIV: Potential to create individualized ARV formulations (e.g., polypills, implants) tailored to patient-specific dosing and release profiles.

9.5.2. Applications for HIV Therapy

- Personalized Dosage Forms: 3D printing can produce tablets or implants with customized drug combinations, doses, and release kinetics, improving adherence and outcomes.
- On-Demand Manufacturing: Enables rapid production of medications for rare HIV subtypes or pediatric patients with unique needs.
- Polypills: Combine multiple ARVs and adjunct therapies into a single, easy-to-administer dosage form.

9.5.3. Analytical and Regulatory Challenges

- Quality Assurance:
    - Uniformity and Stability: Ensuring consistent drug content, dissolution, and stability in each printed unit.
    - Bioavailability: Verifying that 3D-printed formulations achieve therapeutic drug levels comparable to conventional products.
- Process Validation
    - Real-Time Monitoring: Need for in-line analytical tools to assess critical quality attributes during printing.
    - Batch-to-Batch Variability: Each printed batch may be unique, requiring adaptive quality control protocols.
- Regulatory Pathways:
    - Current Gaps: Regulatory frameworks are still evolving to address the flexibility and variability of 3D-printed pharmaceuticals.
    - Documentation: Comprehensive characterization and validation data are required for approval.
    - Material Compatibility: Selection of suitable excipients and printing materials is critical to ensure safety, efficacy, and manufacturability.

9.5.4. Future Directions

- Integration with Digital Health: Linking 3D printers to cloud-based clinical and pharmacogenomic data could enable fully automated, patient-specific medication production.
- Research and Development: Ongoing innovation in printing technologies, materials science, and analytical chemistry will drive the evolution of personalized HIV drug delivery.

9.6. METHOD DEVELOPMENT PROCESS [8] [14]

Comprehensive Guide to Method Development and Validation for Analytical Methods Used to Quantify HIV Antiviral Drugs

This guide provides a detailed, step-by-step approach to developing and validating analytical methods for quantifying antiviral drugs used in HIV/AIDS treatment. Accurate and reliable analytical methods are essential for therapeutic drug monitoring, pharmacokinetic studies, and quality control of HIV medications. The following comprehensive protocol outlines the critical steps involved in method development and validation, with specific considerations for HIV antiretroviral agents such as protease inhibitors and other classes of antiretroviral drugs.

9.7. Method Selection and Initial Planning

9.7.1. Step 1: Literature Review and Method Selection

Start by accomplishing a thorough literature evaluate of present analytical strategies for HIV antiretroviral tablets. An overview posted methodologies for similar compounds to apprehend the analytical challenges and capacity methods. Primarily based on the literature, pick out the most suitable analytical technique for your particular wishes, considering elements together as sensitivity requirements, available resources, and intended software. High-performance liquid chromatography coupled with mass spectrometry (HPLC-MS) has been validated to be particularly effective for HIV protease inhibitors and other antiretrovirals because of its high sensitivity and selectivity34. Different strategies, which include UV spectroscopy, can also be suitable depending on the unique requirements and available instrumentation. Don't forget the physicochemical properties of the target drug(s), predicted attention ranges in biological matrices, and capability interferences while selecting your approach. [8] [14]

9.7.2. Step 2: Method Requirements Definition

Honestly, define the requirements and goals of the analytical technique. Determine the goal analytes (single drug or multiple tablets simultaneously), the biological matrix (plasma, serum, and many others), and the anticipated concentration range. For HIV antiretrovirals, healing drug tracking commonly requires detection in plasma or serum within clinically applicable concentration ranges. Set up preliminary recognition standards for validation parameters based on regulatory recommendations and intended use. For strategies intended for medical healing drug tracking, recall elements which include turnaround time, sample quantity necessities, and price-effectiveness. Many HIV patients require simultaneous tracking of more than one antiretroviral, so methods capable of quantifying more than one drug in a single assay (just like the one defined in seek result4 that may quantify 12 antiretrovirals concurrently) can be particularly treasured. [8] [14]

9.8. Sample Preparation Development

9.8.1. Step 3: Sample Collection and Storage Protocol Development

Broaden protocols for pattern series, dealing with, and garages that ensure certain analyte balance. Define appropriate collection tubes, anticoagulants (if applicable), and storage situations. For plasma samples of HIV patients, series in EDTA or heparin tubes is commonplace, observed with the aid of centrifugation and storage at -20°C or -80°C till analysis. Establish stability parameters for the analytes under diverse storage conditions via initial balance studies. Record the maximum allowable time between pattern series and evaluation, in addition to any special handling requirements. Don't forget potential degradation pathways for specific antiretrovirals—for instance, a few HIV protease inhibitors can be sensitive to mild or pH modifications, requiring precise storage conditions to maintain stability. [8] [14]

9.8.2. Step 4: Sample Preparation Optimization

Expand and optimize an efficient extraction system to isolate the drug(s) from the biological matrix. Commonplace processes for HIV antiretrovirals encompass protein precipitation, liquid-liquid extraction, and strong-section extraction. For example, a simple protein precipitation extraction method, the use of natural solvent,s can be applied to small plasma aliquots (50 µL) as described for HIV protease inhibitors4Examinene one of a kind extraction solvents, volumes, and situations to maximize recuperation at the same time as minimizing matrix consequences. Optimization needs to focus on achieving excessive extraction performance (generally 90% recuperation), accurate reproducibility, and smooth extracts that limit ion suppression in MS detection. The extraction method ought to be practical for routine use in clinical laboratories, taking into account factors such as time, cost, and technical complexity. [8] [14]

9.9. Chromatographic Method Development

9.9.1. Step 5: Initial Chromatographic Conditions

Set up initial chromatographic situations based on the physicochemical properties of the goal analytes and facts from the literature evaluation. For HIV antiretrovirals, reversed-segment HPLC with C18 columns is normally employed34.

Pick suitable beginning conditions for cellular segment composition (typically combos of water and natural solvents like acetonitrile or methanol, with modifiers inclusive of formic acid), column type and dimensions, flow rate, and temperature. Beginn with isocratic situations for simple packages or gradient elution for a couple of analytes or complicated matrices. Preliminary experiments must focus on reaching adequate retention, perfect peak shape, and enough decision between analytes and capability interferences. [8] [14]

9.9.2. Step 6: Systematic Optimization Using Design of Experiments

Apply a structured Design of Experiments (DoE) approach to systematically optimize the chromatographic conditions rather than changing one factor at a time. Central composite design or similar experimental designs can be used to investigate the effects of key parameters and their interactions on method performance5. Identify the most critical factors influencing separation (such as mobile phase composition, pH, column temperature, and gradient profile) and establish their experimental ranges. Perform the designed experiments and analyze the results using statistical software to identify optimal conditions. Response variables typically include retention time, peak shape (tailing factor), resolution between adjacent peaks, and plate count. Create three-dimensional response surface plots to visualize parameter interactions and identify the optimal combination of conditions that provides the best overall performance across all response variables. [8] [14]

9.9.3. Step 7: Detection Parameter Optimization

Optimize detection parameters based on the chosen analytical technique. For HPLC-MS/MS methods, this involves optimizing mass spectrometry parameters including ionization mode (positive or negative electrospray ionization), fragmentor voltage, collision energy, and multiple reaction monitoring (MRM) transitions for each analyte. For HIV protease inhibitors, positive electrospray ionization is typically employed, with specific MRM transitions selected for each drug4. For UV detection methods, determine the optimal wavelength for maximum sensitivity based on the analyte's absorption spectrum. Optimization should focus on maximizing sensitivity while maintaining specificity. For multi-analyte methods, compromise settings may be necessary to accommodate all target compounds within a single analytical run. [8] [14]

9.9.4. Step 8: Internal Standard Selection and Method Finalization

Select an appropriate internal standard to compensate for variations in sample preparation and instrument performance. The internal standard should have similar physicochemical properties to the analytes but be chromatographically resolved from them. For HPLC-MS methods for HIV drugs, deuterated analogues of the target drugs make ideal internal standards when available, though other compounds with similar properties can be used (such as quinoxaline for HIV protease inhibitors)4. Finalize the method by combining the optimized sample preparation procedure with the optimized chromatographic and detection conditions. Perform preliminary evaluations to confirm the method's performance before proceeding to formal validation. The final method should be documented in detail, including all preparation procedures, instrument parameters, and data analysis protocols. [8] [14]

9.10. Analytical Method Validation

9.10.1. Step 9: Validation Plan Development

Develop a comprehensive validation plan based on international guidelines such as ICH, FDA, or EMA requirements. Define the validation parameters to be evaluated (selectivity, linearity, range, accuracy, precision, sensitivity, recovery, and stability) and establish acceptance criteria for each parameter. Design experiments to evaluate each validation parameter with an appropriate number of replicates and concentration levels. For HIV antiretroviral drugs, validation should cover the clinically relevant concentration range, which varies by drug (e.g., therapeutic ranges for protease inhibitors are typically in the μg/mL range)3. The validation plan should clearly define the statistical approaches to be used for data analysis and the decision criteria for method acceptance. [8] [14]

9.10.2. Step 10: Selectivity and Specificity Evaluation

Evaluate the method's selectivity and specificity by analyzing blank matrix samples (e.g., drug-free plasma), blank matrix spiked with the analyte(s) and internal standard, and potential interfering substances. For HIV drugs, potential interferences may include concomitant medications commonly prescribed to HIV patients, such as treatments for opportunistic infections or comorbidities. The method should demonstrate the ability to measure the analyte(s) unequivocally in the presence of these potential interferences. Chromatographic separation should be sufficient to resolve the analyte(s) from endogenous matrix components and other drugs. For MS detection, specific MRM transitions should be monitored to further enhance selectivity. Document any observed interferences and assess their impact on method performance. [8] [14]

9.10.3. Step 11: Linearity and Range Assessment

Establish the linearity of the method by analyzing calibration standards prepared in the biological matrix at a minimum of six concentration levels covering the expected range of concentrations in patient samples. For HIV antiretrovirals, calibration ranges should be established based on expected therapeutic concentrations, which vary by drug (e.g., for protease inhibitors like darunavir, the clinically relevant range might be 0.5-10 μg/mL). Prepare and analyze calibration standards in multiple (typically three) independent runs. Plot the analyte/internal standard response ratio against the nominal concentration and apply appropriate regression methods (typically weighted linear regression). The correlation coefficient (r^2) should exceed 0.99 for acceptability, as demonstrated in the HPLC-MS method for HIV protease inhibitors where r^2 values greater than 0.998 were achieved4. Document the validated range (the interval between upper and lower concentration levels with acceptable accuracy, precision, and linearity). [8] [14]

9.10.4. Step 12: Accuracy and Precision Determination

Evaluate accuracy and precision by analyzing quality control (QC) samples at a minimum of three concentration levels (low, medium, and high) within the calibration range. Prepare QC samples in the biological matrix independently from calibration standards. Assess within-run precision and accuracy by analyzing multiple replicates (typically n=6) in a single analytical run. Evaluate between-run precision and accuracy by analyzing the same QC samples on multiple days (typically 3 or more). Calculate the mean accuracy (% deviation from nominal) and precision (% relative standard deviation) at each concentration level. For HIV antiretroviral methods, mean intra- and inter-day precision should ideally be less than 15% RSD (20% at the lower limit of quantification), and mean accuracy should be within ±15% of the nominal value (±20% at LLOQ)4. The validation results should be comprehensively documented, including all individual measurements, means, standard deviations, and calculated performance metrics. [8] [14]

9.10.5. Step 13: Sensitivity Assessment (LOD and LOQ)

Determine the limit of detection (LOD) and limit of quantification (LOQ) of the method. The LOD represents the lowest concentration that can be reliably distinguished from background noise, while the LOQ represents the lowest concentration that can be quantitatively determined with acceptable accuracy and precision. Calculate the LOD and LOQ either statistically (based on the standard deviation of the response and the slope of the calibration curve) or experimentally (by analyzing progressively diluted samples until predetermined precision criteria are no longer met). For HIV drugs, the LOQ should be sufficiently low to detect concentrations below the therapeutic range, especially for monitoring adherence or in special populations (e.g., pediatric patients). Document the established LOD and LOQ values, along with supporting data demonstrating how these limits were determined. [8] [14]

9.10.6. Step 14: Recovery and Matrix Effect Evaluation

Assess extraction recovery by comparing the response of analyte extracted from the biological matrix to the response of analyte spiked into extracted blank matrix. Evaluate recovery at multiple concentration levels (typically low, medium, and high). For HIV antiretroviral methods, extraction recovery should ideally be consistent across the concentration range and exceed 70%, though lower recoveries may be acceptable if precision is adequate. For MS-based methods, also evaluate matrix effects by comparing the response of analyte in post-extraction spiked samples to the response in pure solvent. Matrix effects should be consistent across different lots of biological matrix and not compromise method performance. For the HPLC-MS method for HIV protease inhibitors, extraction recovery ranged between 93% and 105%, indicating excellent extraction efficiency. [8] [14]

9.10.7. Step 15: Stability Assessment

Evaluate the stability of the analyte(s) under various conditions relevant to sample handling, processing, and analysis. Stability studies typically include: (1) short-term stability at room temperature, (2) long-term storage stability at intended storage conditions (e.g., -20°C or -80°C), (3) freeze-thaw stability through multiple cycles, and (4) post-preparative

stability in the autosampler. For each condition, analyze QC samples at low and high concentrations in triplicate and compare the results to freshly prepared standards. The mean concentration at each level should not deviate by more than 15% from the nominal concentration. For HIV antiretrovirals, which may have different stability profiles, specific stability studies should be designed based on expected sample handling conditions in the intended clinical or research setting. Document all stability data, including storage conditions, time periods, and calculated percentage differences. [8] [14]

9.11. Step 16: Robustness Testing

Evaluate the robustness of the method by deliberately introducing small variations in method parameters to identify those critical to method performance. For HPLC methods, typically varied parameters include mobile phase composition (±2-5%), pH (±0.1-0.2 units), column temperature (±3-5°C), flow rate (±0.1-0.2 mL/min), and different column lots or manufacturers. The impact of these variations on system suitability parameters (retention time, resolution, tailing factor) and quantitative results should be assessed. For robust methods, the observed changes should be minimal and not compromise method performance. Document the robustness testing results, identifying any parameters requiring strict control during routine method execution. [8] [14]

9.12. Method Implementation and Maintenance

9.12.1. Step 17: Method Application to Real Samples

Apply the validated method to analyze real patient samples to demonstrate its practical utility. Collect samples from HIV patients receiving the antiretroviral drug(s) of interest, following the established sample collection and processing protocols. Analyze these samples alongside calibration standards and QC samples according to the validated method. For HIV protease inhibitors like darunavir and ritonavir, the validated HPLC-MS methodology has been successfully applied for routine therapeutic drug monitoring and pharmacokinetic studies in HIV-positive patients4. Evaluate the distribution of measured concentrations against expected therapeutic ranges and assess the method's performance in the intended clinical context. Document any challenges or limitations encountered during the analysis of real samples and implement refinements to the method if necessary. [8] [14]

9.12.2. Step 18: Method Transfer and Standardization (if applicable)

If the method will be used in multiple laboratories, implement a formal method transfer process to ensure consistent performance across different settings. Prepare detailed standard operating procedures (SOPs) describing all aspects of the analytical method. Provide reference standards, quality control materials, and technical training to recipient laboratories. Conduct a method transfer study where both the originating and receiving laboratories analyze identical sets of samples, including calibration standards and QC samples. Compare the results between laboratories using predefined acceptance criteria for agreement. For therapeutic drug monitoring of HIV medications, standardized methods across multiple clinical sites can facilitate data comparison and consistent patient care. Document the method transfer process and results, addressing any discrepancies through collaborative troubleshooting. [8] [14]

9.12.3. Step 19: Continuous Quality Control and Method Maintenance

Implement a continuous quality control program to monitor method performance during routine use. Include system suitability tests at the beginning of each analytical run to verify acceptable chromatographic performance (e.g., resolution, tailing factor, column efficiency). Incorporate quality control samples at multiple concentration levels in each analytical batch to verify accuracy and precision. Consider participation in external quality assessment programs specific to antiretroviral drug analysis when available. Establish criteria for revalidation, such as changes in instrument components, reagent lots, or observed drift in method performance. Maintain comprehensive documentation of all quality control results, system suitability tests, maintenance activities, and any method modifications. For long-term monitoring of HIV patients, consistent analytical performance is essential for reliable interpretation of drug concentration trends. [8] [14]

9.12.4. Step 20: Final Documentation and Reporting

Compile comprehensive documentation of the entire method development and validation process. Prepare a detailed report including the rationale for method selection, development strategy, optimization experiments, validation results,

and conclusions regarding method performance and applicability. The report should clearly state the intended use of the method and any limitations identified during development and validation. For HIV antiretroviral analytical methods, documentation should address specific considerations related to the therapeutic monitoring of these drugs, such as clinically relevant concentration ranges, sampling time considerations, and interpretation guidelines. Ensure all raw data, calculations, and electronic records are properly archived according to regulatory and institutional requirements. This documentation serves as the foundation for method implementation in routine analysis and supports regulatory submissions if required. [8] [14]

9.13. Regulatory Guidelines and Regional Specificity [1] [2] [27]

9.13.1. Global Regulatory Frameworks

Key international tips include the ones from the worldwide Council for Harmonisation (ICH), especially ICH Q2(R2), which defines validation parameters that include specificity/selectivity, accuracy, precision, linearity/variety, detection and quantitation limits, robustness, and device suitability. The FDA and EMA carefully observe these tips, with current updates streamlining validation to house modern analytical strategies, along with multivariate and non-linear methods. Validation must be thorough and finished before pivotal medical trial fabric launch and new drug application (NDA) submission, making sure techniques are fit for ordinary use. [1] [2] [27]

9.13.2. grGreatith the aid of the design (QbD) approach

QbD is more and more promoted via regulatory bodies like the FDA and ICH as a proactive, scientific, and risk-based framework for technique development and validation. It integrates first-rate goal product profiles (QTPP), vital fine attributes (CQA), risk assessment, and lifecycle control to enhance technique robustness and regulatory compliance. QbD enables innovation whilst controlling development costs and regulatory hurdles. [1] [2] [27]

9.13.3. Bioanalytical Technique Validation Specifics

For HIV antivirals, bioanalytical methods—frequently using superior strategies like RP-UHPLC-MS/MS or HILIC-UHPLC-MS/MS—need to validate calibration ranges that cover healing and sub-therapeutic concentrations, frequently down to low ng/mL levels. Matrix effects are a sizable undertaking; therefore, matrix calibration curves and selective pattern practice (e.g., µ-SPE-PT) are hired to ensure accuracy and precision. Validation includes demonstrating sensitivity (LLOQ), selectivity in opposition to endogenous and concomitant drug interferences, recovery, and balance in biological matrices. [1] [2] [27]

Phase-Suitable Validation: Regulatory corporations endorse tailoring validation rigor to the drug development segment. Early clinical levels might also require approach qualification with a little flexibility, while overdue- level and post-approval stages call for complete validation to help protection and efficacy claims. This phased method balances resource use with regulatory expectations and affected person safety. [1] [2] [27]

Local Specificity and aid issues: In resource-constrained areas, inclusive of many Sub-Saharan African international locations, regulatory government may rely on expedited review pathways and reliance on stringent regulatory agencies (SRAs), just like the FDA or EMA for HIV drug approvals. This reliance allows quicker access to crucial drugs despite constrained nearby regulatory capacity. But, local validation and nice manipulation remain critical to ensure drug protection and efficacy in the target population. The National Medicine Regulatory Authority (NMRA) in Zimbabwe exemplifies successful expedited HIV drug approval using leveraging worldwide facts and regulatory reliance. [1] [2] [27]

Stability and forced Degradation studies: Regulatory pointers additionally require balance-indicating methods developed via compelled degradation studies to characterize drug substance stability and degradation products. Such research aid the improvement of strong analytical techniques that make certain drug nice for the duration of shelf existence.

In summary, regulatory hints for HIV antiviral drug analytical method development and validation are grounded in ICH Q2(R2) principles, more advantageous through QbD concepts, and adapted locally to accommodate useful resource constraints and expedite access. Validation needs to comprehensively reveal approach suitability for scientific and best control packages, with a phased approach aligned to drug development stages and nearby regulatory skills. [1] [2] [27]

9.14. Case research and scientific packages of Lenacapavir and Cabotegravir (2020–2023)

9.14.1. Current scientific Trials and Case series

Lenacapavir (LEN) is a novel long-acting (l. A.) Capsid inhibitor approved by way of the FDA for treatment- experienced HIV-1 patients with multidrug resistance. It's far administered subcutaneously every 6 months and has established considerable viral load discount in phase three trials. The CALIBRATE phase 2 trial (2020–2023) evaluated LEN in aggregate with different antiretrovirals in remedy-naive patients, displaying rapid viral suppression (ninety % through week 28) and elevated CD4+ T cell counts as compared to traditional regimens. No resistance advanced in the members meeting, virological failure criteria, indicating sturdy antiviral efficacy and safety. [4] [22] [19] [3] [12]

Cabotegravir (CAB) is an integrase inhibitor used in long-acting injectable formulations, commonly administered intramuscularly every 4 to eight weeks. Lately, a phase I trial brought an ultra-long-acting cabotegravir (CAB-ULA) method that probably doubles the dosing interval to at least 4 months, enhancing adherence and convenience8. CAB is generally combined with rilpivirine (RPV) for long-acting HIV remedy, but RPV's effectiveness is constrained in patients with NNRTI resistance. [4] [22] [19] [3] [12]

A brilliant case collection from four US educational centres (2024) explored the off-label mixture of subcutaneous LEN every 26 weeks with intramuscular CAB (± RPV) each 4 or eight weeks in 34 patients dealing with adherence demanding situations and NNRTI resistance. Viral suppression costs elevated from 47% at baseline to 94% post-treatment, with all patients harboring NNRTI mutations reaching suppression. This looks at support, in addition n medical trials of the LEN/CAB combination, mainly for patients with resistance to contemporary regimens. [4] [22] [19] [3] [12]

9.15. Scientific Programs and Implications

- Remedy for multidrug-resistant HIV: LEN offers a brand-new mechanism of action focused on the viral capsid, powerful in closely treatment-experienced patients.
- Long-appearing regimens for adherence: Combining LEN and CAB as injectables reduces tablet burden and frequency, addressing demanding situations in populations with poor adherence.
- Potential for extended dosing periods: CAB-ULA might also similarly improve patient comfort and retention in care through lowering injection frequency to as soon as every 4 months or longer.
- Use in NNRTI-resistant populations: The LEN/CAB combination indicates promise in overcoming resistance barriers, wherein CAB/RPV is less powerful. Real- global challenges: technical version during the COVID-19 Pandemic
- The COVID-19 pandemic posed good-sized challenges to medical trial conduct and pharmaceutical supply chains globally, impacting the improvement and deployment of more recent drugs like LEN and CAB. [4] [22] [19] [3] [12]
- Supply chain disruptions: Lockdowns and transportation restrictions brought about shortages and delays in reagents, raw materials, and packaging additives crucial for drug manufacturing and laboratory testing. This affected the provision of medical trial substances and recurring monitoring assays[general knowledge].
- Scientific trial adaptations: Many trials shifted to decentralized or hybrid models, incorporating telemedicine, domestic-based drug management, and remote tracking to keep participant engagement whilst minimizing contamination risk.
- Laboratory method variations: Analytical labs confronted reagent shortages and workforce barriers, prompting validation of opportunity assay techniques and reagents for drug quantification and viral load testing. This required rapid method revalidation and regulatory communication to ensure information integrity.
- Impact on pediatric and susceptible populations: access to clinics was confined, complicating pattern collection and drug management, specifically for long-acting injectables requiring healthcare professional transport.

These variations highlight the need for flexible analytical and medical methodologies to ensure continuity of care and research throughout public health emergencies.

Pediatric Formulations: [21] [25] Demanding Situations in the Evaluation of Liquid and Dispersible Formulations Pediatric formulations of antiretrovirals pose analytical challenges, mainly for liquid or dispersible formulations designed to enhance dosing accuracy, palatability, and adherence in kids.

9.16. Balance demanding situations

- Chemical and physical balance: Liquid and dispersible formulations regularly comprise excipients which includes sweeteners, flavoring agents, and suspending dealers that could interact with the lively pharmaceutical component (API), affecting balance. Stability trying out should deal with degradation pathways, consisting of hydrolysis and oxidation, under various storage conditions.
- Microbial infection: Liquid bureaucracy are more vulnerable to microbial boom, necessitating sturdy preservative systems and microbiological testing to make certain protection in the course of shelf existence.
- Shelf lifestyles and storage: Pediatric formulations can also require refrigeration or protection from light, complicating distribution and use in aid-confined settings.

9.17. Palatability and components

- Taste overlaying: bitter apis like antiretrovirals require powerful taste-overlaying strategies the use of sweeteners, flavors, or encapsulation technologies. Analytical strategies should make certain those components do not intervene with drug quantification assays.
- Compatibility of components: Some excipients may affect drug solubility or bioavailability. Analytical strategies must be verified to differentiate the API signal from excipient-associated interferences.

9.18. Analytical technique considerations

- Pattern coaching: Liquid and dispersible formulations require unique pattern instruction steps to ensure homogeneity and accurate dosing at some point of analysis.

- Assay sensitivity and specificity: strategies which includes HPLC or LC-MS/MS ought to be optimized to come across the API in the presence of complex excipient matrices.
- Balance-indicating strategies: Analytical methods need to differentiate between the API and degradation merchandise, ensuring correct balance profiling.

9.19. Regulatory and Realistic Implications

- Pediatric formulations must meet stringent regulatory necessities for high-quality, safety, and efficacy.
- Analytical strategies need to be robust, reproducible, and established for the unique method matrix.
- Palatability and acceptability research are important to ensure adherence in pediatric populations.

10. Conclusion

As we have done the literature review on the analytical Method Development which includes HPLC Validation ,LC-MC/MS of antiretroviral drug for HIV that show crucial function with in the development and testing of analytical techniques that guarantee the effect, safety and exceptional of Antiviral tablet used for HIV treatment. This review is expected to provide new ideas and perspective for researchers and regulator who focus on complexity of drug analysis on HIV

Compliance with ethical standards

Acknowledgments

I would like to express my sincere gratitude to Paramhansa Ramkrishna Maunibaba Shikshan Santha's Anuradha College of Pharmacy, Chikhali, under the esteemed leadership of Dr. R. H. Kale (Principal), for providing the academic environment and resources that have been instrumental in the successful completion of this project. The college's commitment to excellence in pharmaceutical education and research has been a constant source of inspiration and support.

Special thanks go to the faculty and staff members, particularly Prof. Kishore Rodge Sir (Project Guardian), for his invaluable guidance, mentorship, and constructive feedback throughout the project. His expertise and dedication significantly shaped the direction and outcomes of this work. I am equally grateful to all faculty members for their encouragement and unwavering support in fostering our growth as future pharmacists.

I am also thankful to my classmates and peers for their cooperation and camaraderie, which made the learning experience enriching and enjoyable. Their collaborative spirit and shared enthusiasm contributed greatly to the success of this project.

Thank you, Anuradha College of Pharmacy, for being a nurturing ground for our academic and professional aspirations.

Disclosure of conflict of interest

No conflict of interest to be disclosed.

References

[1] International Council for Harmonisation (ICH), Validation of Analytical Procedures: Text and Methodology Q2(R1). Geneva, Switzerland: ICH, 2005.

[2] United States Pharmacopeia (USP), General Chapter <1225>: Validation of Compendial Procedures. Rockville, MD: USP, 2023.

[3] World Health Organization (WHO), Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery, and Monitoring. Geneva, Switzerland: WHO, 2021.

[4] M. Blessy, R. D. Patel, P. N. Prajapati, and Y. K. Agrawal, "Development of forced degradation and stability-indicating studies of drugs—a review," J. Pharm. Anal., vol. 4, no. 3, pp. 159–165, 2014, doi: 10.1016/j.jpha.2013.09.003.

[5] S. K. Patel and S. A. Patel, "Simultaneous estimation of antiretroviral drugs by RP-HPLC method," J. Chromatogr. Sci., vol. 56, no. 4, pp. 336–343, 2018, doi: 10.1093/chromsci/bmy003.

[6] R. N. Rao, N. Venkateswarlu, and R. B. N. Prasad, "Stability-indicating UPLC method for tenofovir alafenamide," J. Pharm. Biomed. Anal., vol. 145, pp. 16–22, 2017, doi: 10.1016/j.jpba.2017.06.013.

[7] D. M. Green, "Analytical method validation for antiviral drugs: Challenges and strategies," Anal. Chem. Insights, vol. 12, pp. 1–10, 2017, doi: 10.1177/1177390117690155.

[8] A. H. Beckett and J. B. Stenlake, Practical Pharmaceutical Chemistry, 4th ed. London, U.K.: CBS Publishers, 2005.

[9] J. V. Gray, Handbook of Analytical Validation. Boca Raton, FL: CRC Press, 2012.

[10] L. R. Snyder, J. J. Kirkland, and J. W. Dolan, Introduction to Modern Liquid Chromatography, 3rd ed. Hoboken, NJ: Wiley, 2010.

[11] Food and Drug Administration (FDA), Bioanalytical Method Validation: Guidance for Industry. Silver Spring, MD: FDA, 2018.

[12] T. D. Karalis, "Quality by design (QbD) in analytical method development," Pharm. Dev. Technol., vol. 24, no. 1, pp. 1–12, 2019, doi: 10.1080/10837450.2018.1509348.

[13] K. Basavaiah et al., "Spectrophotometric determination of efavirenz in pharmaceuticals," Sci. Pharm., vol. 80, no. 3, pp. 619–630, 2012, doi: 10.3797/scipharm.1204-21.

[14] P. C. Sharma, HPLC Methods for Pharmaceutical Analysis. New Delhi, India: CBS Publishers, 2016.

[15] M. E. Swartz and I. S. Krull, Analytical Method Development and Validation. New York, NY: Marcel Dekker, 1997.

[16] G. A. Shabir, "Validation of HPLC methods for pharmaceutical analysis," J. Valid. Technol., vol. 10, no. 2, pp. 1–10, 2004.

[17] S. Gorog, *Ultraviolet-Visible Spectrophotometry in Pharmaceutical Analysis*. Boca Raton, FL: CRC Press, 2018.

[18] C. Hartmann et al., "Validation of analytical methods for HIV drug monitoring," J. Clin. Microbiol., vol. 55, no. 8, pp. 2449–2457, 2017, doi: 10.1128/JCM.00461-17.

[19] J. M. H. van den Elsen et al., "LC-MS/MS for therapeutic drug monitoring of HIV drugs," Clin. Chem., vol. 65, no. 3, pp. 441–450, 2019, doi: 10.1373/clinchem.2018.291377.

[20] P. J. Rudewicz and B. K. Matuszewski, "Bioanalytical method validation for antiviral drugs," Anal. Chem., vol. 74, no. 12, pp. 2719–2732, 2002, doi: 10.1021/ac020066h.

[21] L. Zhou et al., "Stability studies of darunavir under stress conditions," J. Pharm. Biomed. Anal., vol. 166, pp. 366–372, 2019, doi: 10.1016/j.jpba.2019.01.026.

[22] R. S. Singhal and P. R. Patel, "Analytical method development for combination antiretroviral therapy," Chromatographia, vol. 83, no. 1, pp. 45–55, 2020, doi: 10.1007/s10337-019-03814-w.

[23] D. G. Watson, Pharmaceutical Analysis: A Textbook for Pharmacy Students and Pharmaceutical Chemists, 4th ed. Edinburgh, U.K.: Elsevier, 2020.

[24] K. Ferenczi-Fodor et al., "Validation of thin-layer chromatographic methods for pharmaceutical analysis," J. Planar Chromatogr., vol. 33, no. 3, pp. 227–239, 2020, doi: 10.1007/s00764-020-00034-z.

[25] A. K. Dwivedi et al., "Method development and validation for emtricitabine and tenofovir disoproxil fumarate," J. AOAC Int., vol. 102, no. 2, pp. 510–515, 2019, doi: 10.5740/jaoacint.18-0242.

[26] M. R. Euerby and P. Petersson, "HPLC method development for antiviral drugs," J. Sep. Sci., vol. 28, no. 15, pp. 1905–1915, 2005, doi: 10.1002/jssc.200500232.

[27] European Medicines Agency (EMA), Guideline on Bioanalytical Method Validation. Amsterdam, Netherlands: EMA, 2015.

[28] S. Ahuja and H. Rasmussen, HPLC Method Development for Pharmaceuticals. San Diego, CA: Academic Press, 2007.

[29] J. Ermer and P. Nethercote, Method Validation in Pharmaceutical Analysis: A Guide to Best Practice. Weinheim, Germany: Wiley-VCH, 2015.

[30] Y. V. Heyden and A. Nijhuis, "Robustness testing of chromatographic methods," J. Pharm. Biomed. Anal., vol. 14, no. 8-10, pp. 1133–1139, 1996, doi: 10.1016/S0731-7085(96)01744-6.